Journal of Cell Communication and Signaling

, Volume 13, Issue 3, pp 395–405 | Cite as

CLDN10 promotes a malignant phenotype of osteosarcoma cells via JAK1/Stat1 signaling

  • Xiaowei Zhang
  • Xianbin Wang
  • Aiyu Wang
  • Qian Li
  • Ming Zhou
  • Tao LiEmail author
Research Article


In our previous study, the expression profile of tight junction (TJ) protein claudins (CLDNs) in human osteosarcoma (OS) cells was examined, and the data found the CLDN10 was high expressed in OS cells versus fetal osteoblast cells. Hence, we aim to determine the impacts and the molecular mechanisms of CLDN10 in the metastatic phenotype of OS. The exact expression profiles of CLDN10 and phosphorylated Janus kinase 1 (JAK1) in noncancerous bone tissues and OS tissues were detected via a western blotting and immunohistochemistry method. The OS cells with CLDN10 or JAK1 silencing was established via an RNA interference (RNAi) method, and an osteoblast cell line stably expressing CLDN10 was established via cell transfection. Then, the transfection effects and activation states of JAK1/ signal transducer and activator of transcription1 (Stat1) pathway in OS and osteoblast cells were detected via a western blotting assay. Moreover, the metastatic ability of osteoblast cells and OS cells in vitro were evaluated by means of a cell counting kit-8 (CCK8) assay, colony formation assay in soft agar, transwell assay and wound-healing experiment. The present data revealed that CLDN10 and phospho-JAK1 were up-regulated in OS tissues compared with noncancerous bone tissues. Genetic loss of CLDN10 or JAK1 inhibited the activation of the Stat1 and the malignant phenotype in OS cells. To sum up, our study suggested the CLDN10 enhanced the metastatic phenotype of OS cells via the activation of the JAK1/Stat1 signaling pathway.


Claudin-10 Osteosarcoma Janus kinase 1 Signal transducer and activator of transcription1 Metastasis 



Cell counting kit-8




Tight junction


Immunohistochemical analysis


RNA interference




Janus kinase 1


Signal transducer and activator of transcription1



We would like to thank American Journal Experts (AJE) for English language editing. This manuscript was edited for English language by American Journal Experts (AJE).

Author contributions

XZ, XW and AW performed the experiments and analyzed the data. MZ and QL contributed to the conception and design of the study. TL revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics approval (approval no. SDU06384) was approved by the Ethics Committee of Central Hospital of Zibo, Affiliated with Shandong University. This article does not contain any studies with animals performed by any of the authors. The informed consent for participation was obtained from all patients and their parents who participated in this study in an appropriate method.

Consent for publication

Written informed consent was obtained from all patients and their parents who participated in this study.


  1. Chao Y-C, Pan S-H, Yang S-C, Yu S-L, Che T-F, Lin C-W, Tsai M-S, Chang G-C, Wu C-H, Wu Y-Y (2009) Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 179(2):123–133CrossRefGoogle Scholar
  2. de Souza WF, Fortunato-Miranda N, Robbs BK, de Araujo WM, de-Freitas-Junior JC, Bastos LG, Viola JP, Morgado-Diaz JA (2013) Claudin-3 overexpression increases the malignant potential of colorectal cancer cells: roles of ERK1/2 and PI3K-Akt as modulators of EGFR signaling. PLoS One 8(9):e74994. CrossRefGoogle Scholar
  3. D'Souza T, Agarwal R, Morin PJ (2005) Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells. J Biol Chem 280(28):26233–26240CrossRefGoogle Scholar
  4. D'Souza T, Indig FE, Morin PJ (2007) Phosphorylation of claudin-4 by PKCε regulates tight junction barrier function in ovarian cancer cells. Exp Cell Res 313(15):3364–3375CrossRefGoogle Scholar
  5. González-Mariscal L, Tapia R, Chamorro D (2008) Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta Biomembr 1778(3):729–756CrossRefGoogle Scholar
  6. Hamazaki Y, Itoh M, Sasaki H, Furuse M, Tsukita S (2002) Multi-PDZ domain protein 1 (MUPP1) is concentrated at tight junctions through its possible interaction with claudin-1 and junctional adhesion molecule. J Biol Chem 277(1):455–461. CrossRefGoogle Scholar
  7. Hewitt KJ, Agarwal R, Morin PJ (2006) The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6(1):186CrossRefGoogle Scholar
  8. Jeansonne B, Lu Q, Goodenough DA, Chen YH (2003) Claudin-8 interacts with multi-PDZ domain protein 1 (MUPP1) and reduces paracellular conductance in epithelial cells. Cell Mol Biol 49(1):13–21Google Scholar
  9. Koval M (2013) Claudin heterogeneity and control of lung tight junctions. Annu Rev Physiol 75:551–567. CrossRefGoogle Scholar
  10. Li X, Ashana AO, Moretti VM, Lackman RD (2011) The relation of tumour necrosis and survival in patients with osteosarcoma. Int Orthop 35(12):1847–1853. CrossRefGoogle Scholar
  11. Li X, Li Y, Qiu H, Wang Y (2013) Downregulation of claudin-7 potentiates cellular proliferation and invasion in endometrial cancer. Oncol Lett 6(1):101–105CrossRefGoogle Scholar
  12. Merino-Gracia J, Costas-Insua C, Canales MA, Rodriguez-Crespo I (2016) Insights into the C-terminal peptide binding specificity of the PDZ domain of neuronal nitric-oxide synthase: CHARACTERIZATION OF THE INTERACTION WITH THE TIGHT JUNCTION PROTEIN CLAUDIN-3. J Biol Chem 291(22):11581–11595. CrossRefGoogle Scholar
  13. Micke P, Mattsson JS, Edlund K, Lohr M, Jirstrom K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Ponten F, Ekman S, Hengstler J, Woll S, Sahin U, Tureci O (2014) Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer 135(9):2206–2214. CrossRefGoogle Scholar
  14. Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65(21):9603–9606CrossRefGoogle Scholar
  15. Oliveira SS, Morgado-Diaz JA (2007) Claudins: multifunctional players in epithelial tight junctions and their role in cancer. Cell Mol Life Sci 64(1):17–28. CrossRefGoogle Scholar
  16. Ouban A, Ahmed AA (2010) Claudins in human cancer: a review Histology and histopathology 25:83–90.
  17. Philip R, Heiler S, Mu W, Buchler MW, Zoller M, Thuma F (2015) Claudin-7 promotes the epithelial-mesenchymal transition in human colorectal cancer. Oncotarget 6(4):2046–2063. CrossRefGoogle Scholar
  18. Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS, Hwang SG, An S, Yoon G, Gye MC, Yi JM, Kim MJ, Lee SJ (2017) Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 36(8):1167–1168. CrossRefGoogle Scholar
  19. Tabaries S, Siegel PM (2017) The role of claudins in cancer metastasis. Oncogene 36(9):1176–1190. CrossRefGoogle Scholar
  20. Takasawa K, Takasawa A, Osanai M, Aoyama T, Ono Y, Kono T, Hirohashi Y, Murata M, Sawada N (2017) Claudin-18 coupled with EGFR/ERK signaling contributes to the malignant potentials of bile duct cancer. Cancer Lett 403:66–73. CrossRefGoogle Scholar
  21. Tsukita S, Furuse M, Itoh M (1999) Structural and signalling molecules come together at tight junctions. Curr Opin Cell Biol 11(5):628–633CrossRefGoogle Scholar
  22. Usami Y, Chiba H, Nakayama F, Ueda J, Matsuda Y, Sawada N, Komori T, Ito A, Yokozaki H (2006) Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum Pathol 37(5):569–577CrossRefGoogle Scholar
  23. Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L, Zhou R (2008) LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 20(5):1077–1083Google Scholar
  24. Zavala-Zendejas VE, Torres-Martinez AC, Salas-Morales B, Fortoul TI, Montano LF, Rendon-Huerta EP (2011) Claudin-6, 7, or 9 overexpression in the human gastric adenocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate. Cancer Investig 29(1):1–11. CrossRefGoogle Scholar
  25. Zhang X, Ruan Y, Li Y, Lin D, Quan C (2015) Tight junction protein claudin-6 inhibits growth and induces the apoptosis of cervical carcinoma cells in vitro and in vivo. Med Oncol 32(5):148. CrossRefGoogle Scholar

Copyright information

© The International CCN Society 2019

Authors and Affiliations

  1. 1.Department of Orthopedic Surgery, Central Hospital of ZiboAffiliated with Shandong UniversityZiboChina
  2. 2.Center for Translational Medicine, Central Hospital of ZiboAffiliated with Shandong UniversityZiboChina
  3. 3.Department of Rehabilitation, Central Hospital of ZiboAffiliated with Shandong UniversityZiboChina

Personalised recommendations